カテゴリー： 世界, 医療/バイオ, LP Information

世界のメチシリン耐性黄色ブドウ球菌感染症用治療薬市場予測 2023年-2029年

【英語タイトル】Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Market Growth 2023-2029

LP Informationが出版した調査資料（LP23DC08851）・商品コード：LP23DC08851
・発行会社（調査会社）：LP Information
・発行日：2023年11月
・ページ数：94
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後2-3営業日）
・調査対象地域：グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
・産業分野：医薬品＆医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,660 ⇒換算￥549,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,490 ⇒換算￥823,500見積依頼/購入/質問フォーム
Corporate User（閲覧人数制限なし）USD7,320 ⇒換算￥1,098,000見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

LPインフォメーションの最新刊調査レポート「世界のメチシリン耐性黄色ブドウ球菌感染症用治療薬市場」は、過去の販売実績から2022年の世界のメチシリン耐性黄色ブドウ球菌感染症用治療薬の総販売量を検討し、2023年から2029年の予測されるメチシリン耐性黄色ブドウ球菌感染症用治療薬の販売量を地域別・市場分野別に包括的に分析しています。本調査レポートでは、地域別、市場分野別、サブセクター別のメチシリン耐性黄色ブドウ球菌感染症用治療薬の市場規模を掲載し、XXX百万米ドル規模の世界のメチシリン耐性黄色ブドウ球菌感染症用治療薬市場の詳細な分析を提供します。本インサイトレポートは、世界のメチシリン耐性黄色ブドウ球菌感染症用治療薬業界を包括的に分析し、製品セグメント、企業情報、売上、市場シェア、最新動向、M&A活動に関する主要トレンドを明らかにしています。
また、本レポートでは、加速する世界のメチシリン耐性黄色ブドウ球菌感染症用治療薬市場における各社の独自のポジションをより深く理解するために、メチシリン耐性黄色ブドウ球菌感染症用治療薬製品ポートフォリオ、能力、市場参入戦略、市場でのポジション、海外展開に焦点を当て、主要なグローバル企業の戦略を分析しています。

世界のメチシリン耐性黄色ブドウ球菌感染症用治療薬市場規模は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに成長すると予測され、2023年から2029年までの年平均成長率は000%と予測されます。メチシリン耐性黄色ブドウ球菌感染症用治療薬の米国市場は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加し、2023年から2029年までのCAGRは000％と予測されています。メチシリン耐性黄色ブドウ球菌感染症用治療薬の中国市場は、2023年から2029年までの年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されます。メチシリン耐性黄色ブドウ球菌感染症用治療薬のヨーロッパ市場は、2023年から2029年にかけて年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されています。

メチシリン耐性黄色ブドウ球菌感染症用治療薬の世界主要メーカーとしては、Basilea Pharmaceutica Ltd、 The Medicines Company、 Theravance Biopharma、 Allergan、 Merck & Co., Inc、 Pfizer, Incなどを掲載しており、売上の面では、世界の2大企業が2022年にほぼ000％のシェアを占めています。

本レポートでは、製品タイプ、用途、主要メーカー、主要地域、国別のメチシリン耐性黄色ブドウ球菌感染症用治療薬市場の包括的な概要、市場シェア、成長機会などの情報を提供しています。

【市場細分化】

この調査ではメチシリン耐性黄色ブドウ球菌感染症用治療薬市場をセグメンテーションし、種類別 (リポペプチド、オキサゾリジノン、テトラサイクリン、セファロスポリン、リポ糖ペプチド、葉酸拮抗薬、その他)、用途別 (病院、専門クリニック、その他)、および地域別 (アジア太平洋、南北アメリカ、ヨーロッパ、および中東・アフリカ) の市場規模を予測しています。

・種類別区分：リポペプチド、オキサゾリジノン、テトラサイクリン、セファロスポリン、リポ糖ペプチド、葉酸拮抗薬、その他

・用途別区分：病院、専門クリニック、その他

・地域別区分
南北アメリカ（アメリカ、カナダ、メキシコ、ブラジル）
アジア太平洋（中国、日本、韓国、東南アジア、インド、オーストラリア）
ヨーロッパ（ドイツ、フランス、イギリス、イタリア、ロシア）
中東・アフリカ（エジプト、南アフリカ、イスラエル、トルコ、GCC諸国）

【本レポートで扱う主な質問】

・世界のメチシリン耐性黄色ブドウ球菌感染症用治療薬市場の10年間の市場状況・展望は？
・世界および地域別に見たメチシリン耐性黄色ブドウ球菌感染症用治療薬市場成長の要因は何か？
・メチシリン耐性黄色ブドウ球菌感染症用治療薬の市場機会はエンドマーケットの規模によってどのように変化するのか？
・メチシリン耐性黄色ブドウ球菌感染症用治療薬のタイプ別、用途別の内訳は？
・新型コロナウイルス感染症とロシア・ウクライナ戦争の影響は？

********* 目次 *********

レポートの範囲
・市場の紹介
・分析対象期間
・調査の目的
・調査手法
・調査プロセスおよびデータソース
・経済指標
・通貨

エグゼクティブサマリー
・世界市場の概要：メチシリン耐性黄色ブドウ球菌感染症用治療薬の年間販売量2018-2029、地域別現状・将来分析
・メチシリン耐性黄色ブドウ球菌感染症用治療薬の種類別セグメント：リポペプチド、オキサゾリジノン、テトラサイクリン、セファロスポリン、リポ糖ペプチド、葉酸拮抗薬、その他
・メチシリン耐性黄色ブドウ球菌感染症用治療薬の種類別販売量：2018-2023年の販売量、売上、市場シェア、販売価格
・メチシリン耐性黄色ブドウ球菌感染症用治療薬の用途別セグメント：病院、専門クリニック、その他
・メチシリン耐性黄色ブドウ球菌感染症用治療薬の用途別販売量：2018-2023年の販売量、売上、市場シェア、販売価格

企業別世界のメチシリン耐性黄色ブドウ球菌感染症用治療薬市場
・企業別のグローバルメチシリン耐性黄色ブドウ球菌感染症用治療薬市場データ：2018-2023年の年間販売量、市場シェア
・企業別のメチシリン耐性黄色ブドウ球菌感染症用治療薬の年間売上：2018-2023年の売上、市場シェア
・企業別のメチシリン耐性黄色ブドウ球菌感染症用治療薬販売価格
・主要企業のメチシリン耐性黄色ブドウ球菌感染症用治療薬生産地域、販売地域、製品タイプ
・市場集中度分析
・新製品および潜在的な参加者
・合併と買収、拡大

メチシリン耐性黄色ブドウ球菌感染症用治療薬の地域別レビュー
・地域別のメチシリン耐性黄色ブドウ球菌感染症用治療薬市場規模2018-2023：年間販売量、売上
・主要国別のメチシリン耐性黄色ブドウ球菌感染症用治療薬市場規模2018-2023：年間販売量、売上
・南北アメリカのメチシリン耐性黄色ブドウ球菌感染症用治療薬販売の成長
・アジア太平洋のメチシリン耐性黄色ブドウ球菌感染症用治療薬販売の成長
・ヨーロッパのメチシリン耐性黄色ブドウ球菌感染症用治療薬販売の成長
・中東・アフリカのメチシリン耐性黄色ブドウ球菌感染症用治療薬販売の成長

南北アメリカ市場
・南北アメリカの国別のメチシリン耐性黄色ブドウ球菌感染症用治療薬販売量、売上（2018-2023）
・南北アメリカのメチシリン耐性黄色ブドウ球菌感染症用治療薬の種類別販売量
・南北アメリカのメチシリン耐性黄色ブドウ球菌感染症用治療薬の用途別販売量
・アメリカ市場
・カナダ市場
・メキシコ市場
・ブラジル市場

アジア太平洋市場
・アジア太平洋の国別のメチシリン耐性黄色ブドウ球菌感染症用治療薬販売量、売上（2018-2023）
・アジア太平洋のメチシリン耐性黄色ブドウ球菌感染症用治療薬の種類別販売量
・アジア太平洋のメチシリン耐性黄色ブドウ球菌感染症用治療薬の用途別販売量
・中国市場
・日本市場
・韓国市場
・東南アジア市場
・インド市場
・オーストラリア市場
・台湾市場

ヨーロッパ市場
・ヨーロッパの国別のメチシリン耐性黄色ブドウ球菌感染症用治療薬販売量、売上（2018-2023）
・ヨーロッパのメチシリン耐性黄色ブドウ球菌感染症用治療薬の種類別販売量
・ヨーロッパのメチシリン耐性黄色ブドウ球菌感染症用治療薬の用途別販売量
・ドイツ市場
・フランス市場
・イギリス市場
・イタリア市場
・ロシア市場

中東・アフリカ市場
・中東・アフリカの国別のメチシリン耐性黄色ブドウ球菌感染症用治療薬販売量、売上（2018-2023）
・中東・アフリカのメチシリン耐性黄色ブドウ球菌感染症用治療薬の種類別販売量
・中東・アフリカのメチシリン耐性黄色ブドウ球菌感染症用治療薬の用途別販売量
・エジプト市場
・南アフリカ市場
・イスラエル市場
・トルコ市場
・GCC諸国市場

市場の成長要因、課題、動向
・市場の成長要因および成長機会分析
・市場の課題およびリスク
・市場動向

製造コスト構造分析
・原材料とサプライヤー
・メチシリン耐性黄色ブドウ球菌感染症用治療薬の製造コスト構造分析
・メチシリン耐性黄色ブドウ球菌感染症用治療薬の製造プロセス分析
・メチシリン耐性黄色ブドウ球菌感染症用治療薬の産業チェーン構造

マーケティング、販売業者および顧客
・販売チャンネル：直接販売チャンネル、間接販売チャンネル
・メチシリン耐性黄色ブドウ球菌感染症用治療薬の主要なグローバル販売業者
・メチシリン耐性黄色ブドウ球菌感染症用治療薬の主要なグローバル顧客

地域別のメチシリン耐性黄色ブドウ球菌感染症用治療薬市場予測レビュー
・地域別のメチシリン耐性黄色ブドウ球菌感染症用治療薬市場規模予測（2024-2029）
・南北アメリカの国別予測
・アジア太平洋の国別予測
・ヨーロッパの国別予測
・メチシリン耐性黄色ブドウ球菌感染症用治療薬の種類別市場規模予測
・メチシリン耐性黄色ブドウ球菌感染症用治療薬の用途別市場規模予測

主要企業分析
Basilea Pharmaceutica Ltd、 The Medicines Company、 Theravance Biopharma、 Allergan、 Merck & Co., Inc、 Pfizer, Inc
・企業情報
・メチシリン耐性黄色ブドウ球菌感染症用治療薬製品
・メチシリン耐性黄色ブドウ球菌感染症用治療薬販売量、売上、価格、粗利益（2018-2023）
・主要ビジネス概要
・最新動向

調査結果および結論

The global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug players cover Basilea Pharmaceutica Ltd, The Medicines Company, Theravance Biopharma, Allergan, Merck & Co., Inc and Pfizer, Inc, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Methicillin-resistant Staphylococcus aureus (MRSA) is a common bacterial infection pathogen that is more difficult to treat due to its resistance to conventional antibiotics such as methicillin. The most commonly used and most effective antibiotics are vancomycin, norvancomycin, and teicoplanin. Secondly, for patients with contraindications or intolerance of the above drugs, other antibacterial drugs, such as sodium fusidate, can also be used. In some countries and regions, ceftazidime, tigecycline, linezolid, daptomycin, etc. can also be used, all of which have good curative effects.
LPI (LP Information)’ newest research report, the “Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Industry Forecast” looks at past sales and reviews total world Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug sales in 2022, providing a comprehensive analysis by region and market sector of projected Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug sales for 2023 through 2029. With Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug industry.
This Insight Report provides a comprehensive analysis of the global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Lipopeptide
Oxazolidinone
Tetracycline
Cephalosporin
Lipoglycopeptide
Folate Antagonist
Other
Segmentation by application
Hospital
Specialist Clinic
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company’s coverage, product portfolio, its market penetration.
Basilea Pharmaceutica Ltd
The Medicines Company
Theravance Biopharma
Allergan
Merck & Co., Inc
Pfizer, Inc
Key Questions Addressed in this Report
What is the 10-year outlook for the global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug market?
What factors are driving Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug market opportunities vary by end market size?
How does Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

❖ レポートの目次 ❖

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug by Country/Region, 2018, 2022 & 2029
2.2 Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Segment by Type
2.2.1 Lipopeptide
2.2.2 Oxazolidinone
2.2.3 Tetracycline
2.2.4 Cephalosporin
2.2.5 Lipoglycopeptide
2.2.6 Folate Antagonist
2.2.7 Other
2.3 Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales by Type
2.3.1 Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Market Share by Type (2018-2023)
2.3.2 Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue and Market Share by Type (2018-2023)
2.3.3 Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sale Price by Type (2018-2023)
2.4 Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Segment by Application
2.4.1 Hospital
2.4.2 Specialist Clinic
2.4.3 Other
2.5 Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales by Application
2.5.1 Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sale Market Share by Application (2018-2023)
2.5.2 Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue and Market Share by Application (2018-2023)
2.5.3 Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sale Price by Application (2018-2023)
3 Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug by Company
3.1 Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Breakdown Data by Company
3.1.1 Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Annual Sales by Company (2018-2023)
3.1.2 Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Market Share by Company (2018-2023)
3.2 Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Annual Revenue by Company (2018-2023)
3.2.1 Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue by Company (2018-2023)
3.2.2 Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Market Share by Company (2018-2023)
3.3 Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sale Price by Company
3.4 Key Manufacturers Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Product Location Distribution
3.4.2 Players Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug by Geographic Region
4.1 World Historic Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Market Size by Geographic Region (2018-2023)
4.1.1 Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Market Size by Country/Region (2018-2023)
4.2.1 Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Annual Sales by Country/Region (2018-2023)
4.2.2 Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Annual Revenue by Country/Region (2018-2023)
4.3 Americas Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Growth
4.4 APAC Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Growth
4.5 Europe Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Growth
4.6 Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Growth
5 Americas
5.1 Americas Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales by Country
5.1.1 Americas Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales by Country (2018-2023)
5.1.2 Americas Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue by Country (2018-2023)
5.2 Americas Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales by Type
5.3 Americas Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales by Region
6.1.1 APAC Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales by Region (2018-2023)
6.1.2 APAC Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue by Region (2018-2023)
6.2 APAC Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales by Type
6.3 APAC Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug by Country
7.1.1 Europe Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales by Country (2018-2023)
7.1.2 Europe Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue by Country (2018-2023)
7.2 Europe Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales by Type
7.3 Europe Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug by Country
8.1.1 Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales by Country (2018-2023)
8.1.2 Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue by Country (2018-2023)
8.2 Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales by Type
8.3 Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug
10.3 Manufacturing Process Analysis of Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug
10.4 Industry Chain Structure of Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Distributors
11.3 Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Customer
12 World Forecast Review for Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug by Geographic Region
12.1 Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Market Size Forecast by Region
12.1.1 Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Forecast by Region (2024-2029)
12.1.2 Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Forecast by Type
12.7 Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Forecast by Application
13 Key Players Analysis
13.1 Basilea Pharmaceutica Ltd
13.1.1 Basilea Pharmaceutica Ltd Company Information
13.1.2 Basilea Pharmaceutica Ltd Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Product Portfolios and Specifications
13.1.3 Basilea Pharmaceutica Ltd Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Basilea Pharmaceutica Ltd Main Business Overview
13.1.5 Basilea Pharmaceutica Ltd Latest Developments
13.2 The Medicines Company
13.2.1 The Medicines Company Company Information
13.2.2 The Medicines Company Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Product Portfolios and Specifications
13.2.3 The Medicines Company Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 The Medicines Company Main Business Overview
13.2.5 The Medicines Company Latest Developments
13.3 Theravance Biopharma
13.3.1 Theravance Biopharma Company Information
13.3.2 Theravance Biopharma Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Product Portfolios and Specifications
13.3.3 Theravance Biopharma Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Theravance Biopharma Main Business Overview
13.3.5 Theravance Biopharma Latest Developments
13.4 Allergan
13.4.1 Allergan Company Information
13.4.2 Allergan Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Product Portfolios and Specifications
13.4.3 Allergan Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Allergan Main Business Overview
13.4.5 Allergan Latest Developments
13.5 Merck & Co., Inc
13.5.1 Merck & Co., Inc Company Information
13.5.2 Merck & Co., Inc Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Product Portfolios and Specifications
13.5.3 Merck & Co., Inc Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Merck & Co., Inc Main Business Overview
13.5.5 Merck & Co., Inc Latest Developments
13.6 Pfizer, Inc
13.6.1 Pfizer, Inc Company Information
13.6.2 Pfizer, Inc Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Product Portfolios and Specifications
13.6.3 Pfizer, Inc Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Pfizer, Inc Main Business Overview
13.6.5 Pfizer, Inc Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Lipopeptide
Table 4. Major Players of Oxazolidinone
Table 5. Major Players of Tetracycline
Table 6. Major Players of Cephalosporin
Table 7. Major Players of Lipoglycopeptide
Table 8. Major Players of Folate Antagonist
Table 9. Major Players of Other
Table 10. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales by Type (2018-2023) & (K Units)
Table 11. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Market Share by Type (2018-2023)
Table 12. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue by Type (2018-2023) & ($ million)
Table 13. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Market Share by Type (2018-2023)
Table 14. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sale Price by Type (2018-2023) & (US$/Unit)
Table 15. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales by Application (2018-2023) & (K Units)
Table 16. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Market Share by Application (2018-2023)
Table 17. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue by Application (2018-2023)
Table 18. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Market Share by Application (2018-2023)
Table 19. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sale Price by Application (2018-2023) & (US$/Unit)
Table 20. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales by Company (2018-2023) & (K Units)
Table 21. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Market Share by Company (2018-2023)
Table 22. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue by Company (2018-2023) ($ Millions)
Table 23. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Market Share by Company (2018-2023)
Table 24. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sale Price by Company (2018-2023) & (US$/Unit)
Table 25. Key Manufacturers Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Producing Area Distribution and Sales Area
Table 26. Players Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Products Offered
Table 27. Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 28. New Products and Potential Entrants
Table 29. Mergers & Acquisitions, Expansion
Table 30. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales by Geographic Region (2018-2023) & (K Units)
Table 31. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Market Share Geographic Region (2018-2023)
Table 32. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue by Geographic Region (2018-2023) & ($ millions)
Table 33. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Market Share by Geographic Region (2018-2023)
Table 34. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales by Country/Region (2018-2023) & (K Units)
Table 35. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Market Share by Country/Region (2018-2023)
Table 36. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue by Country/Region (2018-2023) & ($ millions)
Table 37. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Market Share by Country/Region (2018-2023)
Table 38. Americas Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales by Country (2018-2023) & (K Units)
Table 39. Americas Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Market Share by Country (2018-2023)
Table 40. Americas Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue by Country (2018-2023) & ($ Millions)
Table 41. Americas Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Market Share by Country (2018-2023)
Table 42. Americas Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales by Type (2018-2023) & (K Units)
Table 43. Americas Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales by Application (2018-2023) & (K Units)
Table 44. APAC Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales by Region (2018-2023) & (K Units)
Table 45. APAC Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Market Share by Region (2018-2023)
Table 46. APAC Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue by Region (2018-2023) & ($ Millions)
Table 47. APAC Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Market Share by Region (2018-2023)
Table 48. APAC Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales by Type (2018-2023) & (K Units)
Table 49. APAC Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales by Application (2018-2023) & (K Units)
Table 50. Europe Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales by Country (2018-2023) & (K Units)
Table 51. Europe Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Market Share by Country (2018-2023)
Table 52. Europe Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue by Country (2018-2023) & ($ Millions)
Table 53. Europe Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Market Share by Country (2018-2023)
Table 54. Europe Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales by Type (2018-2023) & (K Units)
Table 55. Europe Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales by Application (2018-2023) & (K Units)
Table 56. Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales by Country (2018-2023) & (K Units)
Table 57. Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Market Share by Country (2018-2023)
Table 58. Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue by Country (2018-2023) & ($ Millions)
Table 59. Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Market Share by Country (2018-2023)
Table 60. Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales by Type (2018-2023) & (K Units)
Table 61. Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales by Application (2018-2023) & (K Units)
Table 62. Key Market Drivers & Growth Opportunities of Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug
Table 63. Key Market Challenges & Risks of Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug
Table 64. Key Industry Trends of Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug
Table 65. Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Raw Material
Table 66. Key Suppliers of Raw Materials
Table 67. Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Distributors List
Table 68. Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Customer List
Table 69. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Forecast by Region (2024-2029) & (K Units)
Table 70. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Forecast by Region (2024-2029) & ($ millions)
Table 71. Americas Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Forecast by Country (2024-2029) & (K Units)
Table 72. Americas Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Forecast by Country (2024-2029) & ($ millions)
Table 73. APAC Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Forecast by Region (2024-2029) & (K Units)
Table 74. APAC Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Forecast by Region (2024-2029) & ($ millions)
Table 75. Europe Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Forecast by Country (2024-2029) & (K Units)
Table 76. Europe Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Forecast by Country (2024-2029) & ($ millions)
Table 77. Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Forecast by Country (2024-2029) & (K Units)
Table 78. Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Forecast by Country (2024-2029) & ($ millions)
Table 79. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Forecast by Type (2024-2029) & (K Units)
Table 80. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 81. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Forecast by Application (2024-2029) & (K Units)
Table 82. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 83. Basilea Pharmaceutica Ltd Basic Information, Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Manufacturing Base, Sales Area and Its Competitors
Table 84. Basilea Pharmaceutica Ltd Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Product Portfolios and Specifications
Table 85. Basilea Pharmaceutica Ltd Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 86. Basilea Pharmaceutica Ltd Main Business
Table 87. Basilea Pharmaceutica Ltd Latest Developments
Table 88. The Medicines Company Basic Information, Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Manufacturing Base, Sales Area and Its Competitors
Table 89. The Medicines Company Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Product Portfolios and Specifications
Table 90. The Medicines Company Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 91. The Medicines Company Main Business
Table 92. The Medicines Company Latest Developments
Table 93. Theravance Biopharma Basic Information, Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Manufacturing Base, Sales Area and Its Competitors
Table 94. Theravance Biopharma Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Product Portfolios and Specifications
Table 95. Theravance Biopharma Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 96. Theravance Biopharma Main Business
Table 97. Theravance Biopharma Latest Developments
Table 98. Allergan Basic Information, Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Manufacturing Base, Sales Area and Its Competitors
Table 99. Allergan Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Product Portfolios and Specifications
Table 100. Allergan Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 101. Allergan Main Business
Table 102. Allergan Latest Developments
Table 103. Merck & Co., Inc Basic Information, Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Manufacturing Base, Sales Area and Its Competitors
Table 104. Merck & Co., Inc Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Product Portfolios and Specifications
Table 105. Merck & Co., Inc Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 106. Merck & Co., Inc Main Business
Table 107. Merck & Co., Inc Latest Developments
Table 108. Pfizer, Inc Basic Information, Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Manufacturing Base, Sales Area and Its Competitors
Table 109. Pfizer, Inc Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Product Portfolios and Specifications
Table 110. Pfizer, Inc Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 111. Pfizer, Inc Main Business
Table 112. Pfizer, Inc Latest Developments
List of Figures
Figure 1. Picture of Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug
Figure 2. Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Lipopeptide
Figure 10. Product Picture of Oxazolidinone
Figure 11. Product Picture of Tetracycline
Figure 12. Product Picture of Cephalosporin
Figure 13. Product Picture of Lipoglycopeptide
Figure 14. Product Picture of Folate Antagonist
Figure 15. Product Picture of Other
Figure 16. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Market Share by Type in 2022
Figure 17. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Market Share by Type (2018-2023)
Figure 18. Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumed in Hospital
Figure 19. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Market: Hospital (2018-2023) & (K Units)
Figure 20. Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumed in Specialist Clinic
Figure 21. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Market: Specialist Clinic (2018-2023) & (K Units)
Figure 22. Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumed in Other
Figure 23. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Market: Other (2018-2023) & (K Units)
Figure 24. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Market Share by Application (2022)
Figure 25. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Market Share by Application in 2022
Figure 26. Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Market by Company in 2022 (K Units)
Figure 27. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Market Share by Company in 2022
Figure 28. Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Market by Company in 2022 ($ Million)
Figure 29. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Market Share by Company in 2022
Figure 30. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Market Share by Geographic Region (2018-2023)
Figure 31. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Market Share by Geographic Region in 2022
Figure 32. Americas Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales 2018-2023 (K Units)
Figure 33. Americas Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue 2018-2023 ($ Millions)
Figure 34. APAC Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales 2018-2023 (K Units)
Figure 35. APAC Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue 2018-2023 ($ Millions)
Figure 36. Europe Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales 2018-2023 (K Units)
Figure 37. Europe Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue 2018-2023 ($ Millions)
Figure 38. Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales 2018-2023 (K Units)
Figure 39. Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue 2018-2023 ($ Millions)
Figure 40. Americas Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Market Share by Country in 2022
Figure 41. Americas Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Market Share by Country in 2022
Figure 42. Americas Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Market Share by Type (2018-2023)
Figure 43. Americas Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Market Share by Application (2018-2023)
Figure 44. United States Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Growth 2018-2023 ($ Millions)
Figure 45. Canada Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Growth 2018-2023 ($ Millions)
Figure 46. Mexico Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Growth 2018-2023 ($ Millions)
Figure 47. Brazil Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Growth 2018-2023 ($ Millions)
Figure 48. APAC Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Market Share by Region in 2022
Figure 49. APAC Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Market Share by Regions in 2022
Figure 50. APAC Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Market Share by Type (2018-2023)
Figure 51. APAC Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Market Share by Application (2018-2023)
Figure 52. China Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Growth 2018-2023 ($ Millions)
Figure 53. Japan Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Growth 2018-2023 ($ Millions)
Figure 54. South Korea Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Growth 2018-2023 ($ Millions)
Figure 55. Southeast Asia Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Growth 2018-2023 ($ Millions)
Figure 56. India Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Growth 2018-2023 ($ Millions)
Figure 57. Australia Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Growth 2018-2023 ($ Millions)
Figure 58. China Taiwan Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Growth 2018-2023 ($ Millions)
Figure 59. Europe Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Market Share by Country in 2022
Figure 60. Europe Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Market Share by Country in 2022
Figure 61. Europe Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Market Share by Type (2018-2023)
Figure 62. Europe Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Market Share by Application (2018-2023)
Figure 63. Germany Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Growth 2018-2023 ($ Millions)
Figure 64. France Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Growth 2018-2023 ($ Millions)
Figure 65. UK Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Growth 2018-2023 ($ Millions)
Figure 66. Italy Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Growth 2018-2023 ($ Millions)
Figure 67. Russia Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Growth 2018-2023 ($ Millions)
Figure 68. Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Market Share by Country in 2022
Figure 69. Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Market Share by Country in 2022
Figure 70. Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Market Share by Type (2018-2023)
Figure 71. Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Market Share by Application (2018-2023)
Figure 72. Egypt Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Growth 2018-2023 ($ Millions)
Figure 73. South Africa Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Growth 2018-2023 ($ Millions)
Figure 74. Israel Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Growth 2018-2023 ($ Millions)
Figure 75. Turkey Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Growth 2018-2023 ($ Millions)
Figure 76. GCC Country Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Growth 2018-2023 ($ Millions)
Figure 77. Manufacturing Cost Structure Analysis of Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug in 2022
Figure 78. Manufacturing Process Analysis of Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug
Figure 79. Industry Chain Structure of Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug
Figure 80. Channels of Distribution
Figure 81. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Market Forecast by Region (2024-2029)
Figure 82. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Market Share Forecast by Region (2024-2029)
Figure 83. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Market Share Forecast by Type (2024-2029)
Figure 84. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Market Share Forecast by Type (2024-2029)
Figure 85. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Market Share Forecast by Application (2024-2029)
Figure 86. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue Market Share Forecast by Application (2024-2029)


★調査レポート[世界のメチシリン耐性黄色ブドウ球菌感染症用治療薬市場予測 2023年-2029年] (コード：LP23DC08851)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のメチシリン耐性黄色ブドウ球菌感染症用治療薬市場予測 2023年-2029年]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の感染症即時検査キット市場予測 2023年-2029年
  • 世界のアシクロビル治療薬市場予測 2023年-2029年
  • 世界の耐酸性アスファルト市場予測 2023年-2029年
  • 世界の抗早漏薬市場予測 2023年-2029年
  • 世界の耐水性PVCパネル市場予測 2023年-2029年

    • ◆H&Iグローバルリサーチのお客様（例）◆